2026 American Society of Clinical Oncology Annual Meeting
Corbus will present updated clinical data from its Phase 1/2 study of CRB-701, a next-generation Nectin-4 antibody-drug conjugate, at the 2026 American Society of Clinical Oncology Annual Meeting, taking place May 29–June 2, 2026, in Chicago. The presentations will include data from studies evaluating CRB-701 in head and neck squamous cell carcinoma and cervical cancer, with updates on clinical response durability and HNSCC patient subgroup analyses.
Agenda
Presentations and events
Gynecological Cancer
Gynecological Cancer
A phase 1/2 study of the next-generation Nectin-4-targeting antibody–drug conjugate CRB-701 in patients with recurrent or metastatic cervical cancer.
- Presenter
-
Professor Yohann Loriot, Gustave Roussy (Paris)
- Authors
-
Tudor-Eliade Ciuleanu, MD, PhD, Arensia Research Clinic; Dominique Berton, MD, Institut de Cancérologie de l'Ouest; et al
- Abstract
-
#5508
Poster Presentation
Head and Neck Cancer
A phase 1/2 study of the next-generation Nectin-4-targeting antibody–drug conjugate CRB-701 (SYS6002) in patients with recurrent or metastatic head and neck squamous cell carcinoma.
- Authors
-
Charlene Mantia, MD, Glenn J Hanna, MD; Dana Farber, et al
- Abstract
-
#6062 (The abstracts will be available on the ASCO® website on May 21, 2026 at 5:00 p.m. ET.)
- Poster board
-
519
In-Person and Virtual KOL Event
Insights from leading HNSCC experts, followed by a live question and answer session.
- Location
-
Marriott Marquis Chicago
- Panel
-
Ari Rosenberg, MD – University of Chicago Medicine, Glenn Hanna, MD - Dana-Farber Cancer Institute, Cesar Augusto Perez Batista, MD - Sarah Cannon Research Institute
- Registration
-
Register for either virtual or in-person attendance.
